May 6th 2024
PrEP could work for women too, but there's a gap in HIV rates among this demographic, especially Black women. Outside of PrEP's proven effectiveness, the below facts suggest the need for better promotion and more options.
Risk of Cardiovascular Disease Decreased in HIV Patients Who Were Treated With Pitavastatin
October 4th 2023Researchers of a phase 3 trial aimed to determine whether statins, specifically pitavastatin, could reduce the incidence of major adverse cardiovascular events among HIV patients, as the risk of cardiovascular disease is increased in those with HIV infection.
Read More
Enrollment in Early Phase Trial of HIV Vaccine That Uses a Cytomegalovirus Vector Is Underway
September 21st 2023Early results are expected late next year from the phase 1 trial, which is being funded by the National Institute of Allergy and Infecious Diseases, the Bill & Melinda Gates Foundation and Vir Biotechnology, a San Franciso biotech company focused on vaccines and infectious disease.
Read More
In a JAMA Network Open study published Sept. 11, researchers wanted to take a deeper look into PrEP regimens’ impact on cardiometabolic health, as it is understudied. To do so they examined the risk of incident hypertension and statin use among adult health plan members starting PrEP with tenofovir alafenamide fumarate (TAF) compared adults taking tenofovir disoproxil fumarate (TDF).
Read More
Generic Triumeq PD, a First-line HIV Medication For Children, Gets Tentative OK
September 12th 2023The tentative approval by the FDA is through the President’s Emergency Plan for AIDS Relief (PEPFAR) program and is supposed to ease regulatory authority submissions, production and distribution in low- and middle-income countries.
Read More
Study Finds Similar Treatment Outcomes for Monkeypox Regardless of HIV Status
August 27th 2023Researchers of a recent study compared the clinical presentation and treatment outcomes of people with HIV and HIV-negative persons with monkeypox who were treated with tecovirimat, as it was previously unclear if treatment outcomes differed between those with and without HIV.
Read More
Immune Checkpoint Inhibitors Study for People Living With HIV Shows Promising Results
June 22nd 2023Researchers and clinicians have been wary of treating people living with HIV with Keytruda, Opdivo and other immune checkpoint inhibitors because removing an inhibitory step in the immune response was seen as risky for people with compromised immune systems.
Read More